Non-Hodgkin lymphoma classification: Difference between revisions
Preeti Singh (talk | contribs) No edit summary |
Preeti Singh (talk | contribs) |
||
Line 5: | Line 5: | ||
Non-Hodgkin lymphoma may be classified into subtypes according to updated [[WHO]] classification and rate of growth. | Non-Hodgkin lymphoma may be classified into subtypes according to updated [[WHO]] classification and rate of growth. | ||
==Classification== | ==Classification== | ||
===A. Updated WHO classification=== | ===A. Updated WHO classification (2016)=== | ||
* Non-Hodgkin lymphoma may be classified according to updated [[WHO]] classification into 2 groups:<ref name="”cancer">National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/publications/pdq</ref> | * Non-Hodgkin lymphoma may be classified according to updated [[WHO]] classification into 2 groups:<ref name="”cancer">National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/publications/pdq</ref> | ||
:* B-cell neoplasms | :* B-cell neoplasms | ||
Line 46: | Line 46: | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | Lymphoplasmacytic lymphoma | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | Lymphoplasmacytic lymphoma | ||
[[Waldenström's macroglobulinemia|Waldenström's macroglubulinemia]] | [[Waldenström's macroglobulinemia|Waldenström's macroglubulinemia]] | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | Hydroa | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | Hydroa vacciniforme like lymphoproliferative disorder | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Monoclonal gammopathy of undetermined significance]] (MGUS), | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Monoclonal gammopathy of undetermined significance]] (MGUS), | ||
Line 60: | Line 60: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Multiple myeloma|Plasma cell myeloma]] (multiple myloma) | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Multiple myeloma|Plasma cell myeloma]] (multiple myloma) | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Enteropathy-type intestinal T-cell lymphoma]] | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Enteropathy-type intestinal T-cell lymphoma|Enteropathy associated intestinal T-cell lymphoma]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Solitary plasmacytoma of bone | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Solitary plasmacytoma of bone | ||
Line 67: | Line 67: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Extraosseous plasmacytoma | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Extraosseous plasmacytoma | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Indolent T-cell lymphoproliferative disorder of the GI | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Indolent T-cell lymphoproliferative disorder of the GI tract | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Monoclonal immunoglobulin deposition diseases | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Monoclonal immunoglobulin deposition diseases | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Hepatosplenic T-cell lymphoma | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Hepatosplenic T cell lymphoma|Hepatosplenic T-cell lymphoma]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Extranodal marginal zone lymphoma of [[MALT lymphoma|mucosa-associated lymphoid tissue]] (MALT lymphoma) | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Extranodal marginal zone lymphoma of [[MALT lymphoma|mucosa-associated lymphoid tissue]] (MALT lymphoma) | ||
Line 89: | Line 89: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Large B-cell lymphoma with IRF4 rearrangement | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Large B-cell lymphoma with IRF4 rearrangement | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Primary cutaneous | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |Primary cutaneous CD30 T-cell lymphoproliferative disorders | ||
* Lymphomatoid papulosis | |||
* Primary cutaneous anaplastic large cell lymphoma | |||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | [[Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle center lymphoma]] | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | [[Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle center lymphoma]] | ||
Line 111: | Line 113: | ||
*DLBCL associated with chronic inflammation | *DLBCL associated with chronic inflammation | ||
*HHV81 DLBCL, NOS | *HHV81 DLBCL, NOS | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | Angioimmunoblastic T-cell lymphoma | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | [[Angioimmunoblastic T-cell lymphoma]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |T-cell/histiocyte-rich large B-cell lymphoma | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |T-cell/histiocyte-rich large B-cell lymphoma | ||
Line 119: | Line 121: | ||
EBV1 mucocutaneous ulcer | EBV1 mucocutaneous ulcer | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | Nodal peripheral T-cell lymphoma with TFH phenotype | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | Nodal peripheral T-cell lymphoma with TFH phenotype | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Lymphomatoid granulomatosis]] | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Lymphomatoid granulomatosis]] | ||
Line 127: | Line 128: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Primary mediastinal large B-cell lymphoma|Primary mediastinal (thymic) large B-cell lymphoma]] | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Primary mediastinal large B-cell lymphoma|Primary mediastinal (thymic) large B-cell lymphoma]] | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | Breast | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | Breast implant associated anaplastic large-cell lymphoma | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Intravascular large B-cell lymphoma]] | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |[[Intravascular large B-cell lymphoma]] | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |ALK1 large B-cell lymphoma | | style="padding: 5px 5px; background: #F5F5F5; text-align: left;" |ALK1 large B-cell lymphoma |
Revision as of 20:47, 14 December 2018
Non-Hodgkin lymphoma Microchapters |
Differentiating Non-Hodgkin's Lymphoma |
---|
Treatment |
Case Studies |
Non-Hodgkin lymphoma classification On the Web |
American Roentgen Ray Society Images of Non-Hodgkin lymphoma classification |
Risk calculators and risk factors for Non-Hodgkin lymphoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Non-Hodgkin lymphoma may be classified into subtypes according to updated WHO classification and rate of growth.
Classification
A. Updated WHO classification (2016)
- B-cell neoplasms
- T-cell and putative NK-cell neoplasms
B-cell neoplasms | T-cell and putative NK-cell neoplasms |
---|---|
Precursor B-cell neoplasm | Precursor T-cell neoplasm |
Precursor B-acute lymphoblastic leukemia / lymphoblastic lymphoma (LBL) | Precursor T-acute lymphoblastic leukemia / lymphoblastic lymphoma (LBL) |
Mature B-cell neoplasms | Peripheral T-cell and NK-cell neoplasms |
Chronic lymphocytic leukemia / small lymphocytic lymphoma | T-cell prolymphocytic leukemia |
Monoclonal B-cell lymphocytosis | T-cell granular lymphocytic leukemia |
B-cell prolymphocytic leukemia | Chronic lymphoproliferative disorder of NK cells |
Splenic marginal zone lymphoma (± villous lymphocytes)
Splenic B-cell lymphoma/leukemia, unclassifiable 1. Splenic diffuse red pulp small B-cell lymphoma 2. Hairy cell leukemia-variant |
Aggressive NK-cell leukemia |
Hairy cell leukemia | Systemic EBV positive T-cell lymphoma of childhood |
Lymphoplasmacytic lymphoma | Hydroa vacciniforme like lymphoproliferative disorder |
Monoclonal gammopathy of undetermined significance (MGUS),
|
Adult T-cell leukemia/lymphoma |
Heavy chain disease
|
Extranodal T/NK-cell lymphoma, nasal type |
Plasma cell myeloma (multiple myloma) | Enteropathy associated intestinal T-cell lymphoma |
Solitary plasmacytoma of bone | Monomorphic epitheliotropic intestinal T-cell lymphoma |
Extraosseous plasmacytoma | Indolent T-cell lymphoproliferative disorder of the GI tract |
Monoclonal immunoglobulin deposition diseases | Hepatosplenic T-cell lymphoma |
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) | Subcutaneous panniculitis-like T-cell lymphoma |
Nodal marginal zone B-cell lymphoma (± monocytoid B-cells)
pediatric |
Mycosis fungoides |
Follicular lymphoma
|
Sézary syndrome |
Large B-cell lymphoma with IRF4 rearrangement | Primary cutaneous CD30 T-cell lymphoproliferative disorders
|
Primary cutaneous follicle center lymphoma | Primary cutaneous gamma delta T-cell lymphoma
Primary cutaneous CD8 aggressive epidermotropic cytotoxic T-cell lymphoma Primary cutaneous acral CD8 T-cell lymphoma Primary cutaneous CD4 small/medium T-cell lymphoproliferative disorder |
Mantle cell lymphoma
In situ mantle cell neoplasia |
Peripheral T-cell lymphoma, NOS *
Peripheral T-cell lymphoma, not otherwise characterized |
Diffuse large B-cell lymphoma (DLBCL), NOS
|
Angioimmunoblastic T-cell lymphoma |
T-cell/histiocyte-rich large B-cell lymphoma | Follicular T-cell lymphoma |
EBV1 DLBCL, NOS
EBV1 mucocutaneous ulcer |
Nodal peripheral T-cell lymphoma with TFH phenotype |
Lymphomatoid granulomatosis | Anaplastic large cell lymphoma
|
Primary mediastinal (thymic) large B-cell lymphoma | Breast implant associated anaplastic large-cell lymphoma |
Intravascular large B-cell lymphoma | |
ALK1 large B-cell lymphoma | |
Plasmablastic lymphoma | |
Primary effusion lymphoma | |
Burkitt lymphoma
Burkitt-like lymphoma with 11q aberration |
|
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements
High-grade B-cell lymphoma, NOS* |
|
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma |
B. Classification based on rate of growth
- Non-Hodgkin lymphoma may be classified based on rate of growth into 2 groups:[2]
- Low-grade or Indolent lymphoma
- High-grade or Aggressive lymphoma
Grade | Description |
---|---|
Low-grade or Indolent lymphoma |
|
High-grade or Aggressive lymphoma |
|
Non-Hodgkin's Lymphoma | ||
---|---|---|
References
- ↑ National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/publications/pdq
- ↑ "Canadian Cancer Society Grades of non-Hodgkin lymphoma".